UK NICE asks Bayer for Xarelto cost-effectiveness data

13 March 2012

UK health care price watchdog the National Institute for Health and Clinical Excellence (NICE), which is currently reviewing Xarelto (rivaroxaban) from German drug major Bayer (BAY: DE) for the treatment of deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults, has asked the company to provide further evidence relating to the drug’s clinical and cost effectiveness.

The annual incidence of DVT in the general population varies considerably with age, ranging from one in 10,000 for people under 40 years to one in 100 for people over 80 years, the agency noted. People with a previous episode of VTE have a high (30%) chance of suffering a recurrence within 8 years. It is estimated that there will be over 46,000 cases of acute DVT in England and Wales during 2012, rising to nearly 50,000 by 2016 due to growth and aging in the population.

Bayer ready to work with the NICE

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK